Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease-Reference-Cited by-同舟云学术

Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease

Published:2021-01 Issue:1 Volume:19 Page:104-110
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Ollech Jacob E.^ORCID,Normatov Inessa,Peleg Noam^ORCID,Wang Jingzhou^ORCID,Patel Shivani A.^ORCID,Rai Victoria,Yi Yangtian,Singer Jorie^ORCID,Dalal Sushila R.,Sakuraba Atsushi,Cohen Russell D.,Rubin David T.^ORCID,Pekow Joel^ORCID

Funder

Pfizer

Takeda Canada

Merck

AbbVie

Janssen Biotech

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference19 articles.

1. Review article: loss of response to anti-TNF treatments in Crohn's disease;Ben-Horin;Aliment Pharmacol Ther,2011

2. Therapeutic drug monitoring of biologics for inflammatory bowel disease;Colombel;Inflamm Bowel Dis,2012

3. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD;Dulai;Gut,2014

4. Systematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn's disease;Qiu;J Gastroenterol,2017

5. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases;Ungar;Clin Gastroenterol Hepatol,2016

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crohn stricture resolution following treatment with high‐dose ustekinumab;Internal Medicine Journal;2024-08

2. IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction;Journal of Clinical Medicine;2024-07-09

3. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

4. Ustekinumab in pediatric patients with Crohn’s disease: safety, and efficacy results from a multicenter retrospective study in China;Frontiers in Pediatrics;2024-04-11

5. Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease;Journal of Clinical Gastroenterology;2024-04-10